Press – September 16, 2017

Witty Health Inc. Announces the Regulatory Submission of Digital-Drug Combination Product for Metastatic Breast Cancer

Houston, TX – September 16, 2017 – Witty Health Inc., a technology company focused on cancer drug toxicity monitoring and treatment pathways, today announced submission of pre-Request For Designation (RFD) documents for a software-enabled Fulvestrant product for treating certain types of breast cancer to the Office of Combination Products (OCP), Food And Drug Administration. A Request For Designation (RFD) filing helps the OCP to identify and assign reviewing responsibility for the drug within the FDA.

“We are excited to achieve this milestone to determine a regulatory pathway for first of its kind digital pharmaceutical product- Fulvestrant Cancer Treatment Platform (FCTP™)” said Co-Founder Ram Sesha. “Witty Health’s Cancer Treatment Platform (CTP™) is designed to develop value-based cancer pharmaceutical products. We are applying software and machine learning tools to oncology products to improve cancer care. This will enable Witty Health to actively customize its Cancer Treatment Platform (CTP™) to other oncology drugs to improve cancer care. To seek a Fast Track designation, the development is in frequent collaboration with the Food and Drug Administration (FDA).”

“The current cancer treatment model does not monitor a patient’s condition between office visits and it is not working. Fulvestrant Cancer Treatment Platform (FCTP™) is designed to improve outcomes associated with Fulvestrant. This is more so when Fulvestrant is used in combination with CDK 4/6 inhibitors Ibrance®, Abemaciclib, and Kisqali®.  Further, we believe our product can significantly reduce preventable health care costs by reducing ER visits and hospitalizations due to symptom exacerbations as well,” said Dr. Karthik Koduru, the Chief Oncologist of Witty Health.

Fulvestrant

Fulvestrant (marketed under brand name Faslodex® by AstraZeneca) is an Estrogen Receptor Modulator. Fulvestrant is approved for the treatment of metastatic breast cancer intolerant to anti-estrogen therapy and in combination with Pfizer’s palbociclib (Ibrance) for the advanced breast cancer intolerant to endocrine therapy. Fulvestrant, which is likely to lose patent protect protection in January 2021, generated over $ 700 million in revenue during 2016 with an annual estimated growth of around 17%. It is additionally evaluated as combination therapy with Lilly’s Abemaciclib (Lilly), Roche’s Taselisib and three Novartis’s approved drugs Ribociclib (Kisqali), Lapatinib (Tykerb) and experimental drug-Alpelisib.

Cancer Treatment Platform

Witty Health’s Cancer Treatment Platform (CTP™) is a digital platform with a suite of tools that help improve cancer care. It can be connected with up to eight devices: a wireless weighing scale, blood pressure cuff, pulse oximeter, stethoscope, thermometer, multi-scope camera, Electrocardiogram (ECG), and blood glucose monitor. These tools create data which can be remotely uploaded while the patient is video conferencing with the physician – in real-time or offline, from home or office. Cancer Treatment Platform (CTP™) includes drug specific toxicity management pathways to help oncologists address toxicity effectively and promptly to improve Quality of Life (QoL) and potentially improve outcomes of the treatment.

It is protected by a number of novel patent applications covering the treatment with Checkpoint, CDK 4/6, PARP, CR and Factor X inhibitors and pain management during cancer therapy. The Cancer Treatment Platform (CTP™) is customizable to a number of medications: five Checkpoint inhibitors; Opdivo, Keytruda®, Imfinzi, TecentriQ® and Bavencio, three CDK 4/6 inhibitors: Ibrance®, Abemaciclib, and Kisqali®, PARP inhibitor; Lynparza and for any pain medication.

About Witty Health

Witty Health, Inc. (www.wittyhealth.com) is a Houston, TX-based technology company focusing on intelligence-powered, real-time health risk monitoring tools to improve the clinical experience. Witty Health, privately held by employees and outstanding physician/oncology leaders, is redefining the immunotherapy-based cancer treatments through the development and commercialization of its proprietary Cancer Treatment Platform (CTP™). ­­­­­­­ The Company uses the InstaMD platform which includes: a telemedicine-based remote clinic, home health monitoring, patient diagnosis, and messaging application modules. Witty Health Inc. has assembled an experienced management team and promoted by some outstanding physician/oncology leaders.

Media Contact:
Contact Person: Ram Sesha
Witty Health Inc.
5850, San Felipe, Suite 500
Houston. TX 77057

Phone: (713) 470-2580
Email: info@wittyhealth.com

www.wittyhealth.com

This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.

Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest investor report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.